CCRT is the standard of care in the treatment of high-grade glioma; however, tumors usually recur within 12–18 months, and newly developed therapeutic options involving checkpoint inhibitors such as PD-1 and PD-L1 have been associated with minimal improvement in OS and limited efficacy [27]. This evidence concerns the gene PDCD1 and glioma.